Timothy Springer is the Latham Family Professor at Harvard Medical School and a billionaire biotech pioneer known for his foundational work in immunology. He discovered the first integrins and adhesion molecules (ICAMs), discoveries that led to blockbusters like Entyvio and Raptiva. A founding investor in Moderna, he famously turned a $5 million stake into billions, cementing his status as one of the world's wealthiest academics. In 2026, he continues to lead the Institute for Protein Innovation (IPI), a legacy nonprofit he endowed with $210 million to advance open-source protein research. Recently, he was elected a Fellow of the National Academy of Inventors and made headlines for his massive $61 million investment in Tectonic Therapeutic. Beyond science, he is an avid collector of gongshi (Chinese scholar's rocks).

Stephane Bancel is the CEO of Moderna, the biotechnology firm that gained global prominence for its pioneering use of messenger RNA (mRNA) technology. Since taking the helm in 2011, Bancel transitioned the company from a pre-clinical startup into a commercial powerhouse, most notably leading the rapid development and global distribution of one of the first COVID-19 vaccines. His leadership is characterized by an aggressive "platform" approach to drug development, aiming to treat everything from rare genetic diseases to cancer and respiratory viruses by turning human cells into drug factories. Under his tenure, Moderna has become a symbol of the genomic revolution, reshaping the pharmaceutical industry’s traditional R&D timelines.